Special report on the storage, management and actual use of raised funds in 2025
Securities code: 688553 Securities abbreviation: Huiyu Pharmaceutical Announcement number: 2026-024
Sichuan Huiyu Pharmaceutical Co., Ltd.
The storage, management and actual use of annual raised funds
2025
Special report
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
In accordance with the relevant provisions of the China Securities Regulatory Commission's "Supervisory Rules for Funds Raised by Listed Companies" and "Self-Regulatory Supervision Guidelines for Companies Listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operations", Sichuan Huiyu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has prepared the "Special Report on the Deposit, Management and Actual Use of Funds Raised by the Company in 2025" as of December 31, 2025. The relevant situation is now reported as follows:
1. Basic situation of raised funds
(1) Actual amount of funds raised and time of fund arrival
According to the approval of the China Securities Regulatory Commission's "Reply on the Registration of the Initial Public Offering of Sichuan Huiyu Pharmaceutical Co., Ltd." (CSRC Permit [2021] No. 2596), and with the consent of the Shanghai Stock Exchange, the company will use the balance underwriting method as the lead underwriter, CITIC Securities Co., Ltd., to publicly issue RMB to the public. 63,600,000 ordinary shares (A shares) were issued at an issue price of RMB 38.87 per share, raising a total of RMB 2,472,132,000.00. After deducting underwriting and sponsorship fees (excluding value-added tax) of RMB 98,874,763.77, the raised funds were RMB 2,373,257,236.23. In addition, after deducting 12,582,391.77 yuan of new external expenses (excluding value-added tax) directly related to the issuance of equity securities such as online issuance fees, prospectus printing fees, reporting accountant fees, lawyer fees, etc., the company's net raised funds this time was 2,360,674,844.46 yuan.
The above-mentioned raised funds were all received on October 18, 2021. The status was verified by Tianjian Accounting Firm (Special General Partnership), which issued a "Capital Verification Report" (Tianjianyan [2021] No. 11-44).
(2) Basic information on raised funds
As of December 31, 2025, the company has used a total of 1.9246764 million yuan of raised funds, and the total balance of the special account for raised funds is 546.8672 million yuan (including the net amount of interest income minus bank fees). The details are as follows:
Basic information on raised funds
Amount unit: RMB 10,000
Issue Name 2021 Initial Public Offering of Shares
The time for receipt of raised funds is October 18, 2021
This reporting period is from January 1, 2025 to December 31, 2025
Item Amount
Total raised funds 247,213.20, including: excess raised funds 45,335.98 minus: direct payment of issuance expenses 11,145.72
Net raised funds 236,067.48 minus:
Amount used in previous years 181,904.78 Amount used in this year 4,518.04 Temporary supplementary amount
Cash management amount 4,300.00 Bank fees and exchange gains and losses 0.09 Permanent replenishment amount 6,044.82 Add:
Interest income from raised funds 11,086.98 Raised funds redeemed for cash management 4,300.00
- Balance of raised funds at the end of the reporting period 54,686.72
2. Management of raised funds
(1) Management of raised funds
In order to standardize the management and use of raised funds, improve the efficiency and effectiveness of fund use, and protect the rights of investors
In accordance with the "Company Law of the People's Republic of China", "Securities Law of the People's Republic of China" and "Public Fundraising of Listed Companies"
Regulations on the Supervision of Funds" (China Securities Regulatory Commission Announcement [2025] No. 10), "Guidelines for Self-Discipline Supervision of Companies Listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operations" and other relevant laws, regulations and normative documents, combined with the actual situation of the company, the "Sichuan Huiyu Co., Ltd. Fund Raising Management System" (hereinafter referred to as
"Management System"), which clearly stipulates the storage, approval, use, management and supervision of raised funds.
At the same time, the raised funds will be stored in a special account and a special account for raised funds will be established in the bank.
According to the "Management System", the Company implements a special account for depositing raised funds and sets up a special account for raised funds in the bank.
accounts, and together with the sponsor institution CITIC Securities Co., Ltd., on October 15, 2021, they respectively entered into cooperation with the Neijiang Branch of Bank of China Co., Ltd., the business office of Neijiang Branch of Leshan Commercial Bank Co., Ltd., and the Bank of Sichuan
Neijiang Branch of Bank of China Co., Ltd., Chengdu Wuhou Branch of China Merchants Bank Co., Ltd., Chengdu Tianfu Branch of China CITIC Bank Co., Ltd., and Huafu Avenue Branch of Shanghai Pudong Development Bank Co., Ltd. respectively signed the "Tripartite Supervision Agreement on Raised Funds"; the company and its subsidiaries Sichuan Zeyu Pharmaceutical Co., Ltd., together with the sponsor CITIC Securities Co., Ltd., signed the "Tripartite Supervision Agreement for Special Account Storage of Raised Funds" with Neijiang Branch of Leshan Commercial Bank Co., Ltd. on February 18, 2022, which clarified the rights and obligations of all parties. The company, together with the sponsor China Securities Co., Ltd., signed the "Tripartite Supervision Agreement for Special Account Deposit of Raised Funds" with the Neijiang Branch of Leshan Commercial Bank Co., Ltd. on May 18, 2023, which clarified the rights and obligations of all parties; the company reviewed and approved the "Proposal on Changing the Special Account for Part of the Raised Funds" at the first meeting of the second board of directors and the first meeting of the second board of supervisors, and agreed to cancel the subsidiary Sichuan Zeyu Pharmaceutical Co., Ltd. The special account for raised funds (account number 020000461614) established at the Neijiang Branch of Leshan Commercial Bank Co., Ltd. also agreed that the company and its subsidiary Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd., together with the sponsor CITIC Securities Co., Ltd., signed the "Tripartite Supervision Agreement for the Special Account Storage of Raised Funds" with the Neijiang Branch of Leshan Commercial Bank Co., Ltd. on July 4, 2023, clarifying the rights and obligations of all parties. The company held the sixth meeting of the second board of directors on January 16, 2024, and reviewed and approved the "Proposal on Opening a Special Account for Raised Funds and Authorizing the Signing of a Supervision Agreement for the Special Account for Raised Funds", and agreed that the company and its subsidiary Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd., Neijiang Branch of Leshan Commercial Bank Co., Ltd., and the sponsor China Securities Co., Ltd. signed a "Tripartite Supervision Agreement for the Special Account for Raised Funds". There are no major differences between the three-party supervision agreement and the Shanghai Stock Exchange's three-party supervision agreement template, and the company has strictly complied with it when using the raised funds.
(2) Storage of raised funds
- As of December 31, 2025, the company has 7 special accounts for raised funds. The deposit status of raised funds is as follows:
Amount unit: RMB Issuance name 2021 initial public offering of shares
The time for receipt of raised funds is October 18, 2021
Account name Opening bank Bank account number Ending balance Account status Sichuan Huiyu Pharmaceutical Co., Ltd. Leshan City Commercial Bank Co., Ltd.
020000437622 23,340,041.51 Use Zhongfen Co., Ltd. Neijiang Branch
Sichuan Huiyu Haiyue Medical Leshan Commercial Bank Co., Ltd.
020000518918 210,709,232.19 Use Traditional Chinese Medicine Technology Co., Ltd. Neijiang Branch
Sichuan Huiyu Haiyue Medical Leshan Commercial Bank Co., Ltd.
020000545986 142,593,876.74 Use Traditional Chinese Medicine Technology Co., Ltd. Neijiang Branch
Sichuan Huiyu Pharmaceutical Stock
Two shares of the Co., Ltd. Leshan Commercial Bank Co., Ltd. 020000513455 170,224,080.94 Company in use Neijiang Branch of the Co., Ltd.
Issue Name 2021 Initial Public Offering of Shares
The time for receipt of raised funds is October 18, 2021
Account name Opening bank Bank account number Ending balance Account status Sichuan Huiyu Pharmaceutical Co., Ltd. Bank of Sichuan Co., Ltd. 7922010004010464 0
Use Zhongfen Co., Ltd. Sineijiang Branch Sales Department 7
Sichuan Huiyu Haiyue Hospital China CITIC Bank Co., Ltd. 81110010130007711
0 Use Traditional Chinese Medicine Technology Co., Ltd. Chengdu Tianfu Branch 57
Shanghai Pudong Development Bank shares
Sichuan Huiyu Haiyue Hospital 7315007880160000
Co., Ltd. Washington Avenue 0 Use Chinese Medicine Technology Co., Ltd. 0470
branch
Sichuan Huiyu Pharmaceutical Stock Bank of China Co., Ltd.
122623086014 0 Canceled Co., Ltd. Sineijiang Branch
Sichuan Huiyu Pharmaceutical Stock China Merchants Bank Co., Ltd.
128905914010118 0 Canceled Co., Ltd. Chengdu Wuhou Branch
Total 546,867,231.38
3. Actual use of raised funds
(1) Usage of raised funds for investment projects
Please see Appendix 1 of this report for a comparison table of the company’s use of raised funds.
(2) Explanation of abnormal situations in investment projects with raised funds
There were no abnormal situations in the company’s investment projects with raised funds.
(3) Explanation of situations where the benefits of investment projects with raised funds cannot be separately calculated
The company's "Huiyu Innovative Drug Research Institute Construction Project" can significantly improve the company's R&D software and hardware capabilities, accelerate the company's product R&D progress, and enhance the company's future competitiveness. The benefits cannot be calculated separately. Supplementary working capital projects are mainly conducive to the continuous improvement of the company's economic benefits and healthy and sustainable development, and are conducive to enhancing the company's capital strength and meeting the capital needs of the company's operations. The benefits cannot be calculated separately.
(4) Advance investment and replacement of investment projects
During the reporting period, there was no advance investment or replacement in the company's investment projects.
(5) Temporarily supplementing working capital with idle raised funds
During the reporting period, the company did not use idle raised funds to temporarily replenish working capital.
(6) Cash management of idle raised funds and investment in related products
- Review of cash management of raised funds
Amount unit: RMB 10,000
Issue Name 2021 Initial Public Offering of Shares
The time for receipt of raised funds is October 18, 2021
Planned
Plan for cash management Plan end date Cash management approved by the board of directors Plan start date
way period date amount
Buy with high security and flow
October 25, 2024 October 2025
20,000.00 Good liquidity and guaranteed capital October 25-24, 2024
specific investment products
Buy with high security and flow
October 29, 2025 October 2026
60,000.00 Good liquidity and guaranteed capital October 29-28, 2025
specific investment products
- Cash management details of raised funds
Amount unit: RMB 10,000
Issue Name 2021 Initial Public Offering of Shares
The time for receipt of raised funds is October 18, 2021
not yet
Estimated annual entrusted products Product Purchase Start End Return Return Interest entruster Receipt Bank Name Type Amount Date Date Date Repay Amount
Interest Rate Amount Sichuan Hui Shanghai Pudong
Yu Haiyue Development Bank Structure Structure
2025 1 January 2025 2025 1
Pharmaceutical Co., Ltd. Existence Existence 500.00 2.27 0.6 March 7th March 27th March 27th
Technology Co., Ltd. Washington Section
Company Dadao Branch
Sichuan Hui Shanghai Pudong
Yu Haiyue Development Bank Structure Structure
1,800.0 2025 2 February 2025 2025 2
Pharmaceutical Co., Ltd. Existence Existence 2.05 2.36 October 5th 28th October 28th
Technology Co., Ltd. Washington Section
Company Dadao Branch
Sichuan Hui Shanghai Pudong
Yu Haiyue Development Bank Structure Structure
2,000.0 2025 3 March 2025 2025 3
Pharmaceutical Co., Ltd. Existence Existence 2.24 3.11 October 6th October 31st October 31st
Technology Co., Ltd. Washington Section
Company Dadao Branch
(7) Use of excess raised funds to permanently supplement working capital or return bank loans
During the reporting period, the company did not use excess raised funds to permanently replenish working capital or repay bank loans.
(8) Situations in which excess raised funds are used for projects under construction and new projects (including acquisition of assets, etc.) or to repurchase and cancel the company’s shares
During the reporting period, the company did not use excess raised funds for projects under construction or new projects (including acquisition of assets, etc.) or to repurchase and cancel the company's shares.
(9) Usage of surplus raised funds
Amount unit: RMB 10,000 Issuance name 2021 initial public offering of shares
Date of receipt of raised funds: October 18, 2021
Total amount of remaining raised funds 6,044.82 [Note] New project calculation
New projects are reviewed by the board of directors. Projects with surplus funds raised by the shareholders’ meeting. Surplus funds. New projects are planned to be invested in funds raised.
Plan passed through voting Name of review pass Amount Purpose Name Raised funds
Total Funding Date Expiration Date
total amount
Huiyu EU standards
Industrialization of injections for supplementation 2025 5
3,506.02 Not involving the base (Phase II) Liquidity Month 29
Project
Huiyu innovative drugs
To be supplemented by 2025-5
Research institute construction 2,538.80 Not involved
Liquidity Month 29
Project
[Note] As the board of directors reviewed and approved new investment project expenses in the future, the board of directors reviewed and approved the remaining funds to permanently replenish working capital of 61.7243 million yuan, and the actual permanent replenishment of working capital was 60.4482 million yuan.
(10) Other situations of use of raised funds
The company has no other use of raised funds.
4. Change the use of funds for investment projects
(1) Changes to the investment project status of raised funds
Please refer to Appendix 2 of this report for details of the company's change in investment projects with raised funds.
(2) Explanation of situations where the benefits of investment projects with raised funds cannot be separately calculated
There is no situation where the company cannot separately calculate the benefits of investment projects with raised funds.
(3) Explanation of external transfer or replacement of investment projects with raised funds
The company has no external transfer or replacement of investment projects with raised funds.
5. Problems in the use and disclosure of raised funds
In 2025, the company deposited and used the raised funds in a special account in accordance with the provisions and requirements of relevant laws, regulations, and normative documents, and disclosed the use of raised funds in a timely manner. There was no disguised change in the use of raised funds, and there were no violations in the use and management of raised funds.
- The accounting firm’s concluding opinions on the assurance report issued by the company on the deposit and use of the company’s annual raised funds.
Tianjian Accounting Firm (Special General Partnership) believes that the 2025 "Special Report on the Deposit, Management and Actual Use of Raised Funds" prepared by the management of Huiyu Pharmaceutical Company complies with the provisions of the "Self-Regulatory Guidelines for Companies Listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operations (Revised in May 2025)" (Shanghai Securities Fa [2025] No. 69), and truthfully reflects the actual storage, management and actual use of funds raised by Huiyu Pharmaceutical Company in 2025.
- The sponsor’s concluding opinions on the special verification report issued by the company on the deposit and use of the company’s annual raised funds.
After verification, the sponsor agency believes that the deposit, management and use of the company's raised funds in 2025 complied with the requirements of relevant laws, regulations and provisions such as the Supervisory Rules for Funds Raised by Listed Companies, the Shanghai Stock Exchange's Science and Technology Innovation Board Stock Listing Rules, and the Shanghai Stock Exchange's Self-Regulatory Supervision Guidelines for Companies Listed on the Science and Technology Innovation Board No. 1 - Standardized Operations. The raised funds were deposited in a special account and used specifically. There was no disguised change in the use of raised funds and harm to the interests of shareholders, and there was no illegal use of raised funds.
- If the company has raised funds more than twice and used the raised funds separately in the same year, it should be explained separately in the special report.
The company has not raised funds more than twice and used the raised funds separately in the same year.
Attachment: 1. Comparison table of usage of raised funds (2025)
- Changes in the status of investment projects with raised funds
Announcement is hereby made.
Board of Directors of Sichuan Huiyu Pharmaceutical Co., Ltd.
Attachment 1 of April 25, 2026
Comparison table of usage of raised funds
2025
Prepared by: Sichuan Huiyu Pharmaceutical Co., Ltd. Unit of amount: RMB 10,000
Issue name Sichuan Huiyu Pharmaceutical Co., Ltd. Date of receipt of raised funds October 18, 2021 Total raised funds 247,213.20 Total raised funds invested this year 10,562.86 Total cumulative invested raised funds 192,467.64 Total raised funds changed in use 34,000.00 Ratio of total raised funds changed in use 13.75% project
Changed as of the end of the period
reach
Project, as of the end of the period As of the end of the period Total as of the end of the period Whether
Commit to invest in projects Raise investment Raise funds Booking Project feasibility is
Including part of the adjusted committed investment for the year. The cumulative investment amount and investment progress for the year were achieved.
Hechao raised capital investment project Committed investment Can cause major changes Total investment Amount Amount of investment Amount Commitment of investment (%) Current benefits Estimated
Change to nature, total amount, status (such as (1) (2) difference in amount (4)=(2)/(1) benefit
state
Yes) (3)＝(2)-(1)
Date
Huiyu EU standards
2024
Industrialized production of injections 17,923.93 Discomfort
Yes 67,941.00 35,941.00 35,941.00 1,254.89 34,866.57 -1,074.43 97.01 Year 7 No Base (Phase II) Construction [Note] Used
month
Project
Huiyu Innovative Drugs 2024
Not suitable for the construction of research institute R&D Yes 42,790.50 40,790.50 40,790.50 1,520.16 39,510.14 -1,280.36 96.86 Year 7 Not applicable No
Use project months
supplement
Unfit Unfit Supplement working capital Liquidity No 80,000.00 80,000.00 80,000.00 80,000.00 100.00 Not applicable No Use funds
Project
Innovative drugs are still in development
R&D Unsuitable (HY-0002a) Yes 20,000.00 20,000.00 9.43 503.43 -19,496.57 2.52 Yu Yan Not applicable No
Project Use Project Development Level
segment
Project
Innovative drugs are still in development
R&D Unsuitable (HY-0006) Yes 14,000.00 14,000.00 124.35 426.79 -13,573.21 3.05 Yu Yan Not applicable No
Project Use Project Development Level
segment
Surplus raised funds supplemented
Not suitable Not suitable for investment in supplementary flow Flow Not applicable Not applicable 6,044.82 6,044.82 6,044.82 6,044.82 100.00 Not applicable No
use funds funds
2025
High-end Green Drug Production Discomfort
No 28,861.00 28,861.00 28,861.00 1,609.21 14,640.91 -14,220.09 50.73 years 6 Not applicable No Industrial chain extension project construction months
supplement
Replenishment of over-raised funds Discomfort Discomfort
Liquidity No 13,500.00 13,500.00 13,500.00 - 100.00 Not applicable No Liquidity Used
funds
Repurchase of excess raised funds Repurchase Discomfort Discomfort
No 2,974.98 2,974.98 2,974.98 - 100.00 Not applicable No Company shares Shares Used
Total - - 219,592.50 242,112.30 242,112.30 10,562.86 192,467.64 -49,644.66 - - - - Reasons for failure to meet the planned schedule (by specific projects) None
Description of major changes in project feasibility None
On December 14, 2021, the company held the first 19th meeting of the board of directors, and reviewed and approved the "Proposal on Using Raised Funds to Replace Self-raised Funds Pre-invested in Fund-raising Projects and Issue Fees Paid", and agreed to use 211.4794 million yuan of raised funds to replace self-raised funds pre-invested in fund-raising projects. According to the above situation, it has been verified by Tianjian Accounting Firm (Special General Partnership) and issued by it the "Preliminary Investment and Replacement Status of Investment Projects with Raised Funds"
Attestation report on Sichuan Huiyu Pharmaceutical Co., Ltd.’s pre-investment in investment projects and payment of issuance expenses with self-raised funds” (Tianjian Shen [2021] No. 11-250). As of December 31, 2022, the "Huiyu EU Standard Injection Industrialization Base (Phase II) Project" has been replaced with 99.5729 million yuan, and the "Huiyu Innovative Drug Research Institute Construction Project" has been replaced with 111.9065 million yuan, for a total of 211.4794 million yuan. Use of idle raised funds to temporarily supplement working capital None
On October 29, 2025, the company held the 20th meeting of the second board of directors and reviewed and approved the "Proposal on the Company's Use of Temporarily Idle Raised Funds for Cash Management", agreeing that the company will use temporarily idle raised funds with an amount of no more than 600 million yuan (including the principal amount) for cash management on the premise of ensuring that it does not affect the normal progress of the raised funds investment plan, and purchase idle raised funds with high security, good liquidity, and capital guarantee agreements for cash management and investment in related products. Investment products (including but not limited to agreement deposits, call deposits, time deposits, structured deposits, certificates of deposit, income certificates, etc.) are valid within 12 months from the date of approval by the board of directors. Within the aforementioned quota and use period, the funds can be used on a rolling basis. In 2025, the company used idle raised funds to purchase structured deposits and deposit products worth RMB 43 million, and redeemed RMB 43 million, realizing a cumulative income of RMB 61,000. As of December 31, 2025, the balance was RMB 0.0 million.
The actual net amount of funds raised from the issuance was RMB 2,360,674,800, which was higher than the planned investment amount of raised funds and exceeded the raised funds by RMB 453,359,800. The excess funds will be used for working capital related to the company's main business or will be disposed of after fulfilling legal procedures in accordance with laws, regulations and relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange. The company held the 22nd meeting of the first board of directors and the 13th meeting of the first supervisory meeting on April 6, 2022. The meeting reviewed and approved the "Proposal on Using Part of the Over-raised Funds to Permanently Supplement Working Capital" and agreed that the company would use part of the over-raised funds of RMB 135 million to permanently replenish working capital. The permanent replenishment of working capital with part of the excess raised funds this time will not affect the capital demand for the construction of investment projects with raised funds. The company will not make high-risk investments or provide financial assistance to others within 12 months after the permanent replenishment of working capital.
The balance of raised funds is 546.8672 million yuan, which is mainly due to the fact that the project construction has not been completed, the project is still in the research and development stage, and the amount and reasons of the excess raised funds balance
cause.
Other uses of raised funds None
[Note] The Huiyu EU Standard Injection Industrialization Base (Phase II) project will achieve revenue of 351.8517 million yuan in 2025, corresponding to a gross profit of 318.864 million yuan, and a total profit of 179.2393 million yuan.
[Note] The company's super-raised capital investment project "High-end Green Drug Industry Chain Extension Project" has reached the scheduled usable state, and the company has completed the project in July 2025. For details, please refer to the "Announcement on the Closing of Super-raised Fund Investment Projects" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on July 16, 2025 (announcement number: 2025-054).
Attachment 2
Changes to the investment project status of raised funds
2025
Prepared by: Sichuan Huiyu Pharmaceutical Co., Ltd. Unit of amount: RMB 10,000
Issue name Sichuan Huiyu Pharmaceutical Co., Ltd. The date of receipt of the raised funds is October 18, 2021
No Investment after change
Actual projects that have reached the expected amount of raised investment. After the change, the actual cumulative degree of the current year as of the end of the period. The board of directors reviewed the corresponding original implementation after the change and determined the usable status. The feasibility project that was planned to be invested in the fundraising plan this year. The cumulative investment. Actual investment amount (%). (3)=(2)/ time point body to year month) family planning major (1)
effect change benefit
Sichuan
Huiyu EU standard Huiyu EU standard
Huiyu
Quasi-injectable drug production Quasi-injectable drug production Domestic No
Newly built pharmaceutical 17,923.93 [June 2023 Industrial base Jiang 35,941.00 35,941.00 1,254.89 34,866.57 97.01 July 2024 Suitable Project Shares Note] July 21 July 10 (second phase) project (Phase II) For market use
limited
Project
company
Sichuan
Huiyu
Huiyu Innovative Drugs Huiyu Innovative Drugs Haiyue Cheng No 2023
Newly built in 2024 2 Institute of Physics Research Institute of Physics Medicine City 40,790.50 40,790.50 1,520.16 39,510.14 96.86 July 2024 Not applicable Applicable No December
Project Established on the 2nd of the month. Established on the 13th of the month.
limited
company
Sichuan
Huiyu EU standard Huiyu
Innovative drug quasi-injection production Haiyue Cheng No
The R&D project is still in progress 2023 6 2023 7 (HY- Industrialization Base Pharmaceutical Capital 20,000.00 20,000.00 9.43 503.43 2.52 Not applicable Suitable No
Project R&D stage March 21st March 10th 0002a) Project (Phase II) Technology Market Use
Project Limited
company
Huiyu EU Standard Sichuan
Quasi-injection production Huiyu
Innovative drug industrialization base Haiyue Cheng No 2023
The R&D project is still in Phase 2 (HY- (Phase II)) in 2024 Medicine All 14,000.00 14,000.00 124.35 426.79 3.05 Not applicable Suitable No December
Project R&D stage 0006 on March 2nd) Project purpose, Huiyuchuang Technology Market Use 13th
NEW DRUG RESEARCH LIMITED
Hospital construction project company
Total 110,731.50 112,753.50 2,908.83 75,306.93 - - - - - -
- The company comprehensively considers its own business needs, industry development trends and actual operating conditions and other relevant factors, and combines the company's own development strategy and the actual situation of the investment projects, and reduces the total investment of the "Huiyu EU standard change reasons, decision-making procedures and information disclosure quasi-injection industrialization base (phase II) project" by 200 million yuan. After the reduction, the raised funds of 200 million yuan will be used for the company's innovative drug HY-0002a The research and development description of the project (divided into specific fundraising projects) will help enhance the company's R&D strength and promote the R&D project to achieve phased results. The company held the second meeting of the second board of directors and the second meeting of the second board of supervisors on June 21, 2023.
At the meeting, the "Proposal on the Investment Amount, Implementation Content Adjustment and Extension of Some Fund-raising Projects" was reviewed and approved. The 2023 second extraordinary shareholders meeting was held on July 10, 2023, and the "Proposal on the Investment Amount, Implementation Content Adjustment and Extension of Some Fund-raising Projects" was reviewed and approved.
- The company comprehensively considers its own business needs, industry development trends and actual operating conditions and other relevant factors, and combines the company's own development strategy and the actual situation of the investment projects, and reduces the total investment of the "Huiyu EU Standard Injection Industrialization Base (Phase II) Project" and the "Huiyu Innovative Drug Research Institute Construction Project" by 120 million yuan. The total investment is reduced by RMB 20 million, and the reduced raised funds of RMB 140 million will continue to be used for the research and development of the company's innovative drug (HY-0006) project, which will help enhance the company's R&D strength and promote the R&D project to achieve phased results. The company held the fifth meeting of the second board of directors and the fifth meeting of the second board of supervisors on December 13, 2023, and reviewed and approved the "Proposal on the Adjustment and Extension of the Investment Amount, Implementation Content of Some Raised Investment Projects", and held the first extraordinary shareholders meeting of 2024 on February 2, 2024, and reviewed and approved the "Proposal on the Adjustment and Extension of the Investment Amount, Implementation Content of Some Raised Investment Projects".
Situations and reasons for failure to achieve planned progress (distribution tools
None
Sports investment projects)
There is a significant change in the feasibility of the project after the change
None
Description of the situation
Note: Huiyu EU Standard Injection Industrialization Base (Phase II) project will achieve revenue of 351.8517 million yuan in 2025, corresponding to a gross profit of 318.864 million yuan, and a total profit of 179.2393 million yuan.